Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against Esperion Therapeutics, Inc. (“Esperion” or the “Company”) (Nasdaq: ESPR). Investors who purchased or otherwise acquired shares between August 18, 2015 and September 28, 2015, (the “Class Period”), are encouraged to contact the firm in advance of the March 14, 2016, lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the complaint, the Company had no clear path to approval for ETC-1002, the Company’s lead product candidate designed to lower LDL-cholesterol levels. In addition, the FDA had encouraged the Company to initiate a cardiovascular outcomes trial (“CVOT”) and that completion of a CVOT could be necessary prior to approval of ETC-1002.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Goldberg Law PC, Los AngelesMichael Goldberg, Esq., 800-977-7401Brian Schall, Esq., 800-977-7401info@goldberglawpc.com

Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Esperion Therapeutics Charts.
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Esperion Therapeutics Charts.